- Company
- K-made Leclaza monotherapy to be showcased at global meeting
- by Son, Hyung-Min Aug 28, 2024 05:52am
- Korean biopharmaceutical companies continue to gain R&D achievements for targeted anti-cancer drugs. Companies have prepared to present their Korean-made anti-cancer drugs, including Leclaza and Rivoceranib at the 2024 World Conference on Lung Cancer, which will be held September 7-10 in San Diego, USA. Yuhan Pharmaceutical will present
- Company
- Challenges in the evolving lung cancer treatment landscape
- by Son, Hyung-Min Aug 28, 2024 05:51am
- The head-to-head battle between the epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer drugs (NSCLC) Leclaza and Tagrisso has carried on to competition of each drug's combination therapy regimens. This month, the U.S. Food and Drug Administration (FDA) approved Leclaza+Rybrevant as a first-line treatment for EGFR-positive
- Company
- Value of new drugs should be evaluated based on efficacy
- by Hwang, Byung-woo Aug 27, 2024 05:50am
- 'Receiving recognization of the value of new drugs' is one of the key challenges for pharma and biotech companies. With the proportion of new drugs being introduced into Korea rising and the number of homegrown new drugs increasing, the need for a drug pricing policy that recognizes the value of these new drugs has been growing. Recog
- Company
- K-similars won record number of U.S.·Europe nods this year
- by Chon, Seung-Hyun Aug 27, 2024 05:50am
- Korean biopharmaceutical companies have launched the highest number of biosimilars in history this year in the United States and European markets. As Celltrion and Samsung Bioepis won approvals for six biosimilars over eight months in the world's largest market, they topped the previous record of five cases of five years ago. According to sou
- Company
- More urothelial cancer drug options now available in KOR
- by Hwang, Byung-woo Aug 26, 2024 05:46am
- A number of immuno-oncology and antibody-drug conjugate (ADC) drugs are being granted approval as a first-line treatment of urothelial cancer, increasing the treatment options that had previously been dominated by platinum-based chemotherapy. Although they are not yet reimbursed and have yet to become mainstream treatment options, it is expe
- Company
- ‘Lilly will reapply for Retevmo’s reimbursement in Korea’
- by Eo, Yun-Ho Aug 26, 2024 05:46am
- “We will do our best to receive reimbursement for Retevmo in Korea. However, the will of the health authorities is as important” The company has expressed its will to list a RET-targeted therapy option in Korea. The question that remains now is when. Lilly's RET inhibitor Retevmo (selpercatinib) remains non-reimbursed since the compa
- Company
- Colorectal cancer drug Fruzaqla may be introduced in H2
- by Eo, Yun-Ho Aug 26, 2024 05:46am
- A new treatment option is expected to emerge in the field of colorectal cancer later this year. According to industry sources, the final review is underway for the approval of Fruzaqla (fruquintinib), which was designated as a Global Innovative products on Fast Track (GIFT) by the Ministry of Food and Drug Safety in November last year.
- Company
- Expansion of newly launched Kerendia underway in KOR
- by Moon, sung-ho Aug 23, 2024 06:18am
- Since early this year, Kerendia has been covered by reimbursement in clinical practices in South Korea. Kerendia's indication may expand to hypertension as it becomes available for prescriptions at clinical practices. According to the pharmaceutical industry on August 13th, Kerendia (finerenone) is now being used in clinical practices
- Company
- Will the SGLT-2i Jardiance be reimb for CKD in 2H?
- by Eo, Yun-Ho Aug 23, 2024 06:18am
- Attention is focused on whether the SGLT-2 inhibitor Jardiance can settle as a reimbursed prescription option for chronic kidney disease in the second half of the year. According to industry sources, the Health Insurance Review and Assessment Service is currently reviewing the reimbursement expansion of Boehringer Ingelheim and Lilly Kore
- Company
- Yungjin applies for approval of its Ofev generic
- by Hwang, Byung-woo Aug 23, 2024 06:17am
- Yungjin Pharmaceutical announced on the 22nd that it has completed the license application for a generic version of Boehringer Ingelheim's ‘Ofev Soft Cap (Ofev)’ that it had developed by changing the original drug’s soft capsule formulation into a tablet. As a global blockbuster product, Ofev (nintedanib) is widely used in combination
